Home/Pharma News
|
Posted 15/01/2016
It has been a hectic year for biosimilars. One of the most important milestones for biosimilars in 2015 was the finalization by the US Food and Drug Administration (FDA) of its regulatory guidelines for biosimilars. Other subjects of interest for biosimilars were the patent expiries of originator biologicals, clinical trials and extrapolation of indications. Biosimilars remain the hot topic for GaBI Online during 2015 and, in fact, all 10 of the most read articles concern biosimilars.
